COVID‐19 Vaccine Response in People with Multiple Sclerosis

• Published in: Annals of neurology Vol. 91; no. 1; pp. 89 - 100
• Main Authors: Tallantyre, Emma C., Vickaryous, Nicola, Anderson, Valerie, Asardag, Aliye Nazli, Baker, David, Bestwick, Jonathan, Bramhall, Kath, Chance, Randy, Evangelou, Nikos, George, Katila, Giovannoni, Gavin, Godkin, Andrew, Grant, Leanne, Harding, Katharine E., Hibbert, Aimee, Ingram, Gillian, Jones, Meleri, Kang, Angray S., Loveless, Samantha, Moat, Stuart J., Robertson, Neil P., Schmierer, Klaus, Scurr, Martin J., Shah, Sita Navin, Simmons, Jessica, Upcott, Matthew, Willis, Mark, Jolles, Stephen, Dobson, Ruth
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.01.2022; Wiley Subscription Services, Inc
• Subjects: Adult; Antibodies, Viral - blood; Antibodies, Viral - drug effects; Antirheumatic Agents - therapeutic use; Blood; CD20 antigen; Cell number; Confidence intervals; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - immunology; Female; Health risks; Health services; Humans; Immune response; Immune system; Immunocompromised Host; Immunosuppressive agents; Lymphocytes; Lymphocytes T; Male; Medical records; Middle Aged; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Respiratory diseases; SARS-CoV-2; Seroconversion; Seroconversion - drug effects; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; Therapy; United Kingdom; Vaccines; Viral diseases; United Kingdom

Objective The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccines in people with multiple sclerosis (MS). Methods Four hundred seventy‐three people with MS provided one or more...